Look at what is happening to Cassava (SAVA) stock. They announced positive ph 3 data recently for their Alzheimer’s drug, and one of the analyst (likely a short) is questioning data integrity
That is not even close to what is actually going on at SAVA.
The P3 trial has not even started yet. So there was no release of data in be causing the issue. There was no release on any recent data.
The issue (legit or not) is calling into question the integrity of the published data for their early trials that was published quite a while ago.
The idea SAVA are being hammered for not waiting for a published paper is ust another made up storyline to support the idea that what LP is doing is in any way reasonable.
... and one of the analyst (likely a short) is questioning data integrity. They lost more than 50% of their market cap (shaved around $2.6B of their market cap) last week. ... but they are doing what’s best to get DCVAX-L approved by all 4 RAs.
Plenty of anxious investors have been with NWBO and are fed up with management's constant kicking of the can down the road and they already saw how swell it was to wait on an article some time back and it was a dud. It is your prerogative to dismiss these investors as having a short term outlook but in reality their anxiousness and frustration is based upon fairly long term experience with what has been going on and how what has gone on could end up repeating itself and the chance of us somehow having this conversation again during part of 2022 is not anywhere near zero.